Abstract
The role of multidrug resistance (MDR) and p53 functional status in the treatment of paediatric rhabdomyosarcoma is unclear. We have characterized a panel of seven human rhabdomyosarcoma cell lines for MDR and p53 phenotype. None of the cell lines had P-glycoprotein (P-gp) or multidrug resistance-related protein (MRP) detectable by Western blotting, whereas immunohistochemistry suggested that very low levels of MDR proteins may be present in some of the lines. RT-PCR studies indicated that mdr-1, mrp-1 and lrp mRNA was present in 5/7, 7/7 and 5/7 lines respectively. The function of p53 is compromised in six of the lines, either through mutation of the p53 gene or by overexpression of mdm-2. The sensitivity of many of the cell lines to vincristine could be modulated above 2-fold and as high as 16-fold using two modulating agents, PSC833 and VX710 (with VX710 being a significantly more potent modulator of the rhabdomyosarcoma lines). PSC833 also increased vincristine accumulation in all of the lines from 1.2- to 2.2-fold. These results suggest that some of these cell lines have low levels of multidrug resistance. The level of MDR proteins is very low and therefore difficult to detect, but may be sufficient to confer low-level, but clinically relevant, resistance to some cytotoxic agents, especially vincristine. These cell lines will therefore provide a suitable model to test new strategies in treatment and for further understanding relationships between protein expression and drug resistance. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Barrand MA, Heppell-Parton AC, Wright KA, Rabbitts PH and Twentyman PR (1994) A 190-kDa protein overexpressed in non-P-glycoprotein-containing multidrug-resistant resistant cells and its relationship to the MRP gene. J Natl Cancer Inst 86: 110–117.
Bordow SB, Haber M, Madafiglio J, Cheung B, Marshall GM and Norris MD (1994) Expression of the multidrug resistance-associated protein (MRP) gene correlates with amplification and overexpression of the N-myc oncogene in childhood neuroblastoma. Cancer Res 54: 5036–5040.
Chan HSL, Thorner PS, Haddad G and Ling V (1990) Immunohistochemical detection of P-glycoprotein – Prognostic correlation in soft-tissue sarcoma of childhood. J Clin Oncol 8: 689–704.
Chaudhary, and Roninson (1993) Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J Natl Cancer Inst 85: 632–639.
Cole SPC, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AMV and Deeley RG (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258: 1650–1654.
Cowie FJ, Pinkerton CR, Phillips M, Dick G, Judson I, McCarthy PT and Flanagan RJ (1995) Continuous-infusion verapamil with etoposide in relapsed or resistant paediatric cancers. Br J Cancer 71: 877–881.
Cowie FJ, Pritchard-Jones K, Renshaw J and Pinkerton CR (1998) Multidrug resistance modulation in rhabdomyosarcoma and neuroblastoma cell lines. Int J Oncol 12: 1143–1149.
Douglass EC, Valentine M, Etcubanas E, Parham D, Webber BL, Houghton PJ, Green AA and Houghton JA (1987) A specific chromosomal abnormality in rhabdomyosarcoma. Cytogenet Cell Genet 45: 148–155.
Enzinger FM and Weiss SW (1983) Soft Tissue Tumours. CV Mosby Co: St. Louis
Enzinger FM and Weiss SW (1995) Soft Tissue Tumours. CV Mosby Co: St. Louis
Felix CA, Chavez Kappel C, Mitsudomi T, Nau MM, Tsokos M, Crouch GD, Nisen PD, Winick NJ and Helman LJ (1992) Frequency and diversity of p53 mutations in childhood rhabdomyosarcoma. Cancer Res 52: 2243–2247.
Ford JM (1996) Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitisers. Eur J Cancer 32A: 991–1001.
Garvin AJ, Stanley WS, Bennett DD, Sullivan JL and Sens DA (1986) The in vitro growth, heterotransplantation, and differentiation of a human rhabdomyosarcoma cell line. Am J Pathol 125: 208–217.
Germann UA, Shlyakhter D, Mason VS, Zelle RE, Duffy JP, Galullo V, Armistead DM, Saunders JO, Boger J and Harding MW (1997 a) Cellular and biochemical characterization of VX-710 as a chemosensitizer: reversal of P-glycoprotein-mediated multidrug resistance in vitro. Anticancer Drugs 8: 125–140.
Germann UA, Ford PJ, Shlyakhter D, Mason VS and Harding MW (1997 b) Chemosensitization and drug accumulation effects of VX-710, verapamil, cyclosporin A, MS-209 and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance-associated protein MRP. Anticancer Drugs 8: 141–155.
Hayashi Y, Sugimoto T, Horii Y, Hosoi H, Inazawa J, Kemshead JT, Inaba T, Hanada R, Yamamoto K, Gown AM and Sawada T (1990) Characterization of an embryonal rhabdomyosarcoma cell line showing amplification and over-expression of the N- myc oncogene. Int J Cancer 45: 705–711.
Houghton JA, Houghton PJ and Webber BL (1982) Growth and characterization of childhood rhabdomyosarcoma as xenografts. J Natl Cancer Inst 68: 437–443.
Keleti J, Quezado MM, Abaza MM, Raffeld M and Tsokos M (1996) The MDM2 oncoprotein is overexpressed in rhabdomyosarcoma cell lines and stabilizes wild-type p53 protein. Am J Pathol 149: 143–151.
Kelland LR, Bingle L, Edwards S and Steel GG (1989) High intrinsic radiosensitivity of a newly established and characterised human embryonal rhabdomyosarcoma cell line. Br J Cancer 59: 160–164.
Kondo S, Kondo Y, Hara H, Kaakaji R, Peterson JW, Morimura T, Takeuchi J and Barnett GH (1996) mdm2 gene mediates the expression of mdr1 gene and P-glycoprotein in a human glioblastoma cell line. Br J Cancer 74: 1263–1268.
Kuttesch JF, Parham DM, Luo X, Meyer WH, Bowman L, Shapiro DN, Pappo AS, Crist WM, Beck WT and Houghton PJ (1996) P-Glycoprotein expression at diagnosis may not be a primary mechanism of therapeutic failure in childhood rhabdomyosarcoma. J Clin Oncol 14: 886–900.
Lane DP (1992) p53, Guardian of the genome. Nature 358: 15–16.
Lowry OH, Rosebrough NJ, Lewis Farr A and Randall RJ (1951) Protein measurements with the folin phenol reagent. J Biol Chem 193: 265–275.
McAllister RM, Melnyk J, Finkelstein JZ, Adams EC and Gardner MB (1969) Cultivation in vitro of cells derived from a human rhabdomyosarcoma. Cancer 24: 520–526.
Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55–63.
Naito M and Tsuruo T (1997) New multidrug-resistance-reversing drugs, MS-209 and SDZ PSC833. Cancer Chemother Pharmacol 40: S20–S24.
O’Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, Scudiero DA, Monks A, Sausville EA, Weinstein JN, Friend S, Fornace AJ and Kohn KW (1997) Characterization of the p53 tumour suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 57: 4285–4300.
Pappo AS, Shapiro DN, Crist WM and Maurer HM (1995) Biology and therapy of paediatric rhabdomyosarcoma. J Clin Oncol 13: 2123–2139.
Pestell KE, Medlow CJ, Titley JC, Kelland LR and Walton MI (1998) Characterisation of the P53 status, BCL-2 expression and radiation and platinum drug sensitivity of a panel of human ovarian cancer cell lines. Int J Cancer 77: 913–918.
Pinkerton CR (1996) Multidrug resistance reversal in childhood malignancies – potential for a real step forward?. Eur J Cancer 32A: 641–644.
Scheper RJ, Broxterman HJ, Scheffer GL, Kaaijk P, Dalton WS, van Heijningen THM, van Kalken CK, Slovak ML, de Vries EGE, van der Valk P, Meijer CJLM and Pinedo HM (1993) Overexpression of a Mr 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res 53: 1475–1479.
Sharp SY, Rowlands MG, Jarman M and Kelland LR (1994) Effects of a new antioestrogen, idoxifene, on cisplatin- and doxorubicin-sensitive and -resistant human ovarian carcinoma cell lines. Br J Cancer 70: 409–414.
Sharp SY, Rogers P and Kelland LR (1995) Transport of cisplatin and bis-acetato-ammine dichlorocyclohexamine platinum (IV) (JM216) in human ovarian carcinoma cell lines: Identification of a plasma membrane protein associated with cisplatin resistance. Clin Cancer Res 1: 981
Stein U, Walther W, Laurencot CM, Scheffer GL, Scheper RL and Shoemaker RH (1997) Tumour necrosis factor-a and expression of the multidrug resistance associated genes LRP and MRP. J Natl Cancer Inst 89: 807–813.
Stratton MR, Moss S, Warren W, Patterson H, Clark J, Fisher C, Fletcher CDM, Ball A, Thomas M, Gusterson BA and Cooper CS (1990) Mutation of the p53 gene in human soft tissue sarcomas: association with abnormalities of the RB1 gene. Oncogene 5: 1297–1301.
Towbin H, Staehelin T and Gordon J (1979) Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedures and some applications. Proc. Natl Acad Sci USA 76: 350
Wurl P, Taubert H, Bache M, Kroll J, Meye A, Berger D, Siermann A, Holzhausen H-J, Hinze R, Schmidt H and Rath F-W (1996) Frequent occurrence of p53 mutations in rhabdomyosarcoma and leiomyosarcoma, but not in fibrosarcoma and malignant neural tumours. Int J Cancer 69: 317–323.
Yanagisawa T, Newman A, Coley H, Renshaw J, Pinkerton CR and Pritchard-Jones K (1999) Biricodar (VX-710; Incel (TM)): An effective chemosensitiser in neuroblastoma. Br J Cancer 80: 1190–1196.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Cocker, H., Pinkerton, C. & Kelland, L. Characterization and modulation of drug resistance of human paediatric rhabdomyosarcoma cell lines. Br J Cancer 83, 338–345 (2000). https://doi.org/10.1054/bjoc.2000.1273
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1054/bjoc.2000.1273
Keywords
This article is cited by
-
The palladacycle complex AJ-5 induces apoptotic cell death while reducing autophagic flux in rhabdomyosarcoma cells
Cell Death Discovery (2019)
-
Simvastatin-induced compartmentalisation of doxorubicin sharpens up nuclear topoisomerase II inhibition in human rhabdomyosarcoma cells
Naunyn-Schmiedeberg's Archives of Pharmacology (2013)
-
Effects of standard chemotherapy on tumor growth and regulation of multidrug resistance genes and proteins in childhood rhabdomyosarcoma
Pediatric Surgery International (2007)
